Prime Therapeutics joins letter of support for biosimilar interchangeability - Prime Therapeutics
Prime Therapeutics joins letter of support for biosimilar interchangeability
Letter led by The Biosimilars Council and the Association for Accessible Medicines
Prime Therapeutics joins nearly 40 leading health care-related organizations in signing a letter sent to U.S. Senate and House of Representatives health committee leaders in support of the Biosimilar Red Tape Elimination Act. This legislation would remove the distinction between biosimilars and interchangeable biosimilars.
For more information, read the full press release and the letter.
About Prime Therapeutics
Prime Therapeutics LLC (Prime) is a diversified pharmacy solutions organization. We offer innovative pharmacy benefit management, specialty and medical drug management, and state government solutions to millions of people across the country. At Prime, we’re reimagining pharmacy solutions to provide the care we’d want for our loved ones. We challenge the way it’s always been done to develop intelligently designed solutions that deliver savings, simplicity and support to help people achieve better health. For more information, visit us at PrimeTherapeutics.com or follow us on LinkedIn.